A prespecified meta-analysis of the clinical development program for the dual GIP/GLP-1 receptor co-agonist tirzepatide concluded that tirzepatide did not increase major cardiovascular events in participants with Type 2 diabetes [51]. This evidence concerns the gene GIP and type 2 diabetes mellitus.